
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside
Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021